For over a century, transfusion of convalescent plasma from recovered individuals has been tried as a therapeutic approach when a novel pathogen emerges. As the world awaits SARS-CoV-2 vaccines to be tested and safely deployed, the rapidity with which antiviral monoclonal antibodies can be isolated and engineered offers an attractive alternative option for passive immunization. In this Comment, Jonathan Abraham highlights the potential of passive immunization strategies for COVID-19.

中文翻译：

---

COVID-19中的被动抗体疗法。

一个多世纪以来，当一种新的病原体出现时，尝试从恢复的个体中输出恢复性血浆作为一种治疗方法。随着世界等待对SARS-CoV-2疫苗进行测试和安全部署，可以分离和设计抗病毒单克隆抗体的快速性为被动免疫提供了有吸引力的替代选择。乔纳森·亚伯拉罕（Jonathan Abraham）在本评论中强调了COVID-19被动免疫策略的潜力。